Narasimhan is confident that Novartis will achieve its goal of increasing sales by an average of 5% annually by 2028.

What if we would have watched it for six months? Like, I possibly couldn’t be here talking to you and have lived my life six ...

Meanwhile, Novartis has gained two new FDA approvals in the US for its breast cancer drug Kisqali and Fabhalta which is used ...

On Tuesday, Novartis AG (NYSE:NVS) reported third-quarter sales of $12.823 billion, up 9% (+10% on constant currency), ...

As expected, Novartis’ radioligand therapy Pluvicto crossed the blockbuster sales threshold with one quarter still left of 2024. | Novartis didn't use a priority review voucher for Pluvicto's key ...

Swiss pharma giant Novartis AG NVS reported better-than-expected results for the third quarter of 2024. Core earnings ...

Novartis exceeded analyst expectations in the third quarter, driven primarily by the strong U.S. sales of Cosentyx, as well ...

The pharmaceutical giant raised its full-year guidance for the third time this year after higher third-quarter profit and ...

Novartis posted third-quarter results that beat analysts' estimates and raised its full-year outlook, buoyed by strong sales ...

Novartis AG boosted its annual profit guidance for the third straight quarter, helped by rising sales of its blockbuster ...

If the FDA approves the drug in this setting, it "would triple the number of ... Sales of Novartis' CDK4/6 inhibitor Kisqali ...